Teva tots up $34B in financing for Allergan deal; Hetero rolls out Rituxan biosim in India;

@FiercePharma: ICYMI: Suit says CVS manipulated generic drug prices. Item | Follow @FiercePharma

@EricPFierce: As #Hospira expands recall of #ketorolac to 37M vials you've got to wonder what Pfizer thinks. Article | Follow @EricPFierce

@CarlyHFierce: #ICYMI Friday: Ackman's 'wolf pack' drove Allergan into foreign hands, former CEO says. More | Follow @CarlyHFierce

> Teva Pharmaceutical Industries ($TEVA) lined up more than $30 billion in financing for its $40 billion buyout of Allergan's ($AGN) generics business, with 11 lenders committing to the deal. Report

> Hetero Pharma rolled out its biosimilar version of Roche's ($RHHBY) Rituxan in India, under the brand name Maball; it will compete with versions from Dr. Reddy's Laboratories and Intas. Release

> Gilead Sciences' ($GILD) hepatitis C sales growth may be slowing, but with more than 2 million patients still untreated in the U.S., it's not going to run out of new business anytime soon. Report

> European regulators recommended Novartis' ($NVS) Revolade to treat severe aplastic anemia who haven't responded to immunosuppressive therapy. Report

> Citing the risk of hacking, the FDA recommended that hospitals stop using Hospira's ($HSP) Symbiq medication infusion pump. Report

Medical Device News

@FierceMedDev: ICYMI Friday: Upstart gets $6M to back the first FDA-cleared, OTC conception assistance device. Article | Follow @FierceMedDev

@VarunSaxena2: ResMed acquires China's Curative Medical to get bigger in sleep disorder devices. Item | Follow @VarunSaxena2

@EmilyWFierce: $OSUR got an FDA OK for emergency use of its rapid Ebola test. Press release | Follow @EmilyWFierce

> U.S. Army scientists roll out innovative blood loss monitor device. More

> Bard gets additional CMS reimbursement for its drug-coated angioplasty balloon. Story

Biotech News

@FierceBiotech: ICYMI Friday: Merck's Ebola vaccine is 100% successful in interim Phase III results. Report | Follow @FierceBiotech

@JohnCFierce: Is it just me, or is $SHPG's Ornskov overrated? Shire chief Ornskov bets $300M on another eye drug bolt-on buyout. Story | Follow @JohnCFierce

@DamianFierce: Charming addition to the drug co. nonsense lexicon: "biobetter." More | Follow @DamianFierce

> Sorrento buys into biosimilars with a Chinese antibody deal. Report

> Lexicon rockets up after a positive PhIII study sets up an NDA. Story

> AstraZeneca deepens its Isis ties with a $65M R&D pact. Article

Animal Health News

> VCA ups 2015 guidance as Q2 sales and profits soar past expectations. More

> Heska doubles Q2 operating income but misses on revenue. Report

> Schein misses Q2 estimates on currency woes and sales challenges. Story

> IDEXX shares climb on record diagnostics placements and Q2 earnings gain. Article

> Report: 'Precision farming' set to revolutionize livestock care. More

Biotech IT News

> Y Combinator continues push into bioinformatics with investment in Cofactor Genomics. News

> NIH to bankroll initiatives to build Cancer Genomics Cloud Pilots into R&D programs. Report

> Ex-BGI CEO's next move? A $1.6B push to find a 'formula for life.' More

> First startups graduate from Illumina Accelerator as deadline for next phase nears. Story

> Venter's HLI plans to ramp up sequencing capacity as more pharma deals near fruition. Article

Pharma Marketing News

> Express Scripts kicks another batch of meds off its preferred formulary. Item

> Pfizer's hot-selling Ibrance gets even hotter with new $710M sales estimate for 2015. News

> Sanofi and MannKind launch Afrezza DTC ad campaign in stealth mode. Story

> Shyft Analytics: Targeted drugs need a data-fueled marketing shift. Article

> Can a dwindling rep tally keep Vivus' obesity med in the game? More

And Finally ... The value of the Type 2 diabetes market is expected to hit $39 billion by 2021. Report

Suggested Articles

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.